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Insulin drives the global anabolic response to
nutrient ingestion, regulating both carbohydrate
and lipid metabolism. Previous studies have demon-
strated that Akt2/protein kinase B is critical to insu-
lin’s control of glucose metabolism, but its role in
lipid metabolism has remained controversial. Here,
we show that Akt2 is required for hepatic lipid accu-
mulation in obese, insulin-resistant states induced
by either leptin deficiency or high-fat diet feeding.
Lepob/ob mice lacking hepatic Akt2 failed to amass
triglycerides in their livers, associated with and
most likely due to a decrease in lipogenic gene
expression and de novo lipogenesis. However, Akt2
is also required for steatotic pathways unrelated to
fatty acid synthesis, as mice fed high-fat diet had
reduced liver triglycerides in the absence of hepatic
Akt2 but did not exhibit changes in lipogenesis.
These data demonstrate that Akt2 is a requisite
component of the insulin-dependent regulation of
lipid metabolism during insulin resistance.
INTRODUCTION
Among its numerous functions, the mammalian liver serves both
as a repository for stored nutrients and an organ that senses,
integrates, and controls the metabolic state of the organism.
As a metabolic tissue, the liver responds to multiple inputs,
including hormones, neuronal impulses, and nutrients. Following
the ingestion of food, the dominant signals to the liver are insulin
and absorbed nutrients, particularly glucose, which serves as
a key substrate and a first messenger providing information to
the liver (Postic et al., 2007). Understanding how the liver
processes these diverse inputs becomes even more challenging
when one considers pathological states associated with overnu-
trition, the incidences of which are reaching epidemic propor-
tions throughout the world (Doria et al., 2008). Here, it becomes
difficult to distinguish protective from maladaptive processes,
though there is little doubt that the accumulation in the liver ofCell Mlarge quantities of macromolecules, such as neutral lipid, has
unmistakable potential for serious toxicity (Browning andHorton,
2004; Savage et al., 2007). Thus, the study of hepatic metabo-
lism has justifiably attracted considerable attention in recent
years.
During the transition from fasting to the fed state, insulin stim-
ulates hepatic glycogen synthesis and suppresses hepatic
gluconeogenesis, resulting in suppression of glucose production
by the liver (Petersen et al., 1998; Saltiel, 2001). Loss-of-function
experiments have shown that the protein kinase Akt (also known
as protein kinase B) is central to the hepatic actions of insulin on
glucose output, though a recent report has questioned the role of
Akt as a cell-autonomous intermediate in insulin signaling (Chen
et al., 2009; Cho et al., 2001a; Garofalo et al., 2003; Gross et al.,
2008). Nonetheless, the prevalent model of hepatic insulin
signaling is that activated Akt phosphorylates and inhibits the
transcription factor FoxO, peroxisome proliferator-activated
receptor-coactivator-1a (PGC-1a), and others, thereby termi-
nating expression of the rate-controlling enzymes of gluconeo-
genesis (Gross et al., 2008; Li et al., 2007). During insulin resis-
tance, this process is blunted, and the persistence of hepatic
glucose output following a meal compounds diminished glucose
uptake into muscle, resulting in postprandial hyperglycemia
(Saltiel, 2001). However, in a seminal essay, McGarry argued
persuasively that the view of type 2 diabetes mellitus (T2DM)
as a disease of glucose metabolism is purely historical and
that the lipid abnormalities are equally intrinsic to the pathophys-
iology (McGarry, 1992). Certainly, T2DM is associated with
a characteristic dyslipidemia, and the vast majority of obese
T2DM individuals with insulin resistance have abnormal accumu-
lation of triglyceride in their livers, so-called nonalcoholic fatty
liver disease (NAFLD) (Petersen et al., 2005; Postic and Girard,
2008a). Moreover, the high serum triglycerides and low HDL
cholesterol of insulin resistance predispose to cardiovascular
disease, the predominant morbidity associated with T2DM,
and NAFLD itself can progress to hepatitis (Browning and Hor-
ton, 2004; Williams, 2008). However, our understanding of the
mechanistic processes governing hepatic lipidmetabolism is still
rudimentary.
During times of nutritional abundance, the liver converts
substrate into triglyceride for local storage as well as export in
the form of very low-density lipoprotein (VLDL). This process isetabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 405
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posttranslational modification, and substrate supply (Postic
andGirard, 2008b). Most recent experiments have been directed
toward investigating the transcriptional control of de novo lipo-
genesis, for which insulin and glucose activate overlapping
sets of genes via the sterol regulatory element-binding protein
1c (SREBP1c) and the carbohydrate response element-binding
protein (ChREBP), respectively (Koo et al., 2001; Postic et al.,
2007; Postic and Girard, 2008a). Though each is required for
the maximal accumulation of hepatic triglyceride during insulin
resistance in mice, the relative roles of these two transcription
factors in the development of NAFLD and under more physiolog-
ical conditions remains unclear (Dentin et al., 2006; Postic and
Girard, 2008a; Yahagi et al., 2002). Moreover, the relative contri-
bution of de novo lipogenesis to hepatic triglyceride accumula-
tion has been controversial, though recent data suggest that it
might account for as much as 25%–30% of the triglyceride in
livers of patients with NAFLD (Donnelly et al., 2005). In the
studies described below, we consider the downstream signaling
pathway that insulin utilizes to promote hepatic lipid accumula-
tion and, in particular, the induction of SREBP1c, a question
for which a consensus answer has yet to emerge. For example,
hepatic overexpression of constitutively active Akt increases
lipid synthesis, resulting in NAFLD and hypertriglyceridemia, as
does hepatic deficiency of PTEN, a negative regulator of PI3K-
dependent protein kinases including Akt (Horie et al., 2004;
Ono et al., 2003; Stiles et al., 2004). Akt mediates insulin’s effect
on SREBP1c expression in cell culture, but studies in vivo have
argued that atypical protein kinase C (aPKC) is the responsible
intermediary signaling protein (Fleischmann and Iynedjian,
2000; Hegarty et al., 2005; Matsumoto et al., 2003; Porstmann
et al., 2005; Taniguchi et al., 2006). Here, we present an in vivo
model that is inherently defective in insulin signaling due to
loss of hepatic Akt2, the major isoform expressed in liver, and
utilize these mice to evaluate the role of Akt2 in lipid synthesis
and accumulation.
RESULTS
Germline Akt2 Deficiency Prevents NAFLD
in Lepob/ob Mice
The serine-threonine kinase Akt exists as three highly related iso-
forms, Akt1–3, each encoded by a distinct gene. Based on
studies of mice with interruptions in each locus, Akt2 is the major
paralog mediating insulin’s effects on glucose metabolism,
whereas Akt1 and Akt3 are more important to growth (Chen
et al., 2001; Cho et al., 2001a, 2001b; Easton et al., 2005; Garo-
falo et al., 2003). Akt2 is the predominant isoform expressed in
insulin target tissues, such as liver, muscle, and adipose tissue,
and Akt2/mice exhibit glucose intolerance and a mild diabeticCell Mphenotype (Cho et al., 2001a; Garofalo et al., 2003). Although
the role of Akt2 in glucose homeostasis has been established,
its influence on lipid metabolism in vivo remains controversial.
To resolve this, we crossed Akt2/ mice with leptin-deficient
Lepob/ob mice. The Lepob/ob Akt2+/+ mice were substantially
heavier than Lep+/+ Akt2+/+ littermates at 12 weeks of age and
had large, lipid-laden livers. However, deletion of both alleles
of Akt2 led to a dramatic reduction of both body and liver weight
in the Lepob/ob mouse, with loss of one allele of Akt2 resulting in
an intermediate decrease (Figures 1A and 1B). Triglyceride accu-
mulation in the livers of Lepob/ob mice under both fed and fasted
conditions was completely prevented by loss of both alleles of
Akt2, and, as above, mice heterozygous for Akt2 demonstrated
intermediate protection from fatty liver (Figures 1C and 1D).
Deletion of Akt2 exacerbated the impairment of glucose homeo-
stasis in Lepob/ob mice, as indicated by an elevation in fasted
glucose and insulin levels compared with Lepob/ob Akt2+/+ mice
(Figures 1E and 1F). Of interest, hyperglycemia was not wors-
ened in the Lepob/ob Akt2+/mice, suggesting that redistribution
of hepatic lipid to other organs was not the cause of the aggra-
vated insulin resistance.
Accumulation of hepatic triglyceride in Lepob/ob mice is asso-
ciated with an increase in de novo lipogenesis (Bray and York,
1979; Shimomura et al., 1999). Therefore, we measured hepatic
fatty acid synthesis and incorporation into triglycerides using
deuterated water as a biosynthetic tracer. Lepob/ob Akt2+/+
mice demonstrated greater de novo lipogenesis compared to
Lep+/+Akt2+/+ mice, but this was reduced in both Lepob/ob
Akt2+/ and Lepob/ob Akt2/ mice (Figure 1G). Nonesterified
free fatty acids (NEFA) were unchanged or increased in Lepob/ob
Akt2/ compared to Lepob/ob Akt2+/+ mice, and there was an
increase in serum triglyceride levels (Table S1 available online).
In addition, loss of Akt2 resulted in a modest decrease in serum
cholesterol, but no change in serum ketone bodies in Lepob/ob
mice (Table S1).
Generation of Lepob/ob Liver-Specific Akt2 Null Mice
In the experiments described above, the cell nonautonomous
effects of germline deletion of Akt2 confound the interpretation
of changes in hepatic lipid content and metabolism. To clarify
this, we generated mice with liver-specific deletion of Akt2.
Mice containing an allele of Akt2 in which exons 3 and 4 are
flanked by loxP sires (Akt2lox/lox) were crossed with mice ex-
pressing Cre recombinase under the control of the albumin
promoter with an a-fetoprotein enhancer (AFP). Progeny were
crossed with Lepob/ob mice, and offspring were assessed for
deletion of Akt2 selectively in the liver. As shown in Figure S1,
AFP;Akt2lox/lox and Lepob/ob AFP;Akt2lox/lox mice lacked hepatic
Akt2 protein while showing no compensatory changes in the
levels of Akt1 or decrease in Akt2 protein in other tissues.Figure 1. Deletion of Akt2 in Lepob/ob Mice Results in Decreased Hepatic Triglycerides and De Novo Lipogenesis
(A and B) Body weight (A) or liver weight (B) of 12-week-old fed male mice.
(C and D) Hepatic triglyceride levels of 12-week-old fed (C) or overnight fasted (D) male mice.
(E and F) Blood glucose (E) and insulin (F) levels in 8-week-old overnight fasted male mice.
(G) De novo lipogenesis. 12-week-oldmalemicewere injectedwith D2O after a 5 hr fast and sacrificed after 3 hr, and liver was removed and analyzed for palmitate
by GC/MS.
All values are expressed as mean ± SEM. n = 5–6. *p < 0.05 versus Lep+/+ Akt2+/+, and **p < 0.05 versus Lepob/ob Akt2+/+ by one-way ANOVA using Newman-
Keuls posttest.etabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 407
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weight compared to Akt2lox/lox mice or AFP;Akt2+/+ mice,
Lepob/ob AFP;Akt2lox/lox mice weighed less than both Lepob/ob
Akt2lox/lox and Lepob/ob AFP;Akt2+/+ mice (Figure 2A and data
not shown). This decrease in body weight was due to propor-
tional reductions in both lean and fat mass, such that relative
body composition remained unchanged (Figure S2A). The
decreased body weight could not be attributed to changes in
food intake or energy expenditure, which were indistinguishable
in Lepob/ob mice with or without hepatic Akt2 (Figures S2B and
S2C). AFP;Akt2lox/lox mice had mildly elevated fasting glucose
levels compared with Lepob/ob Akt2lox/loxmice but did not exhibit
any change in insulin levels (Figures 2C and 2D).
Loss of Hepatic Akt2 Reduces Hepatic Triglyceride
Levels, De Novo Lipogenesis, and Lipogenic
Gene Expression in the Lepob/ob Mouse
Hepatic deletion of Akt2 resulted in decreased liver weight in the
Lepob/ob mouse, due at least in part to a reduction in triglyceride
content under both fed and fasted conditions (Figures 2B, 2E,
and 2F). This decrement does not solely reflect the decreased
body weight in Lepob/ob AFP;Akt2lox/lox mice, as even compared
to weight-matched controls, Lepob/ob AFP;Akt2lox/lox mice ex-
hibited reduced hepatic triglyceride content under fed condi-
tions (Lepob/ob Akt2lox/lox: 56.7 ± 3.34 mg/g TG, 34.9 ± 1.6 g
body weight; Lepob/ob AFP;Akt2lox/lox:12.3 ± 1.43 mg/g TG,
38.7 ± 1.1 g body weight). Fasted serum triglyceride levels
were decreased in Lepob/ob AFP;Akt2lox/lox mice compared with
Lepob/ob Akt2lox/lox mice, whereas fed values were unchanged
(Table S2). Serum cholesterol was decreased in Lepob/ob mice
upon liver-specific deletion of Akt2, but other serum markers of
lipid metabolism were largely unaffected (Table S2). The content
and distribution of long-chain fatty acyl-CoA were not signifi-
cantly different among any of the genotypes, though there was
a trend toward a decrease in the two monounsaturated fatty
acids palmitoleate (C16:1) and oleate (C18:1) in Lepob/ob AFP;
Akt2lox/lox compared with Lepob/ob Akt2lox/lox livers (Figure 2G).
De novo lipogenesis was elevated in the Lepob/ob Akt2lox/lox
mice, and loss of hepatic Akt2 reversed this effect, as was previ-
ously observed with whole-body loss of Akt2 (Figure 2H). These
results demonstrate that Akt2 is required in the liver for the
increases in both hepatic de novo lipogenesis and triglyceride
accumulation in Lepob/ob mice.
The augmented de novo lipogenesis in the Lepob/ob mouse is
associated with an increase in lipogenic gene expression, in
particular SREBP1c and its transcriptional targets (Shimomura
et al., 1999). In the present studies, we confirmed the predicted
increases in the mRNAs for SREBP1c, steroyl CoA desaturase
(SCD1), fatty acid synthase (FAS), acetyl COA carboxylase
(ACC), ATP citrate lyase (ACL), glycerol phosphate acyltransfer-
ase (GPAT), and glucokinase (GCK) in Lepob/ob Akt2lox/lox livers
and, moreover, found that all of these increases were prevented
by loss of hepatic Akt2 (Figure 3). Expression of ChREBP
was unchanged, but its target pyruvate kinase (L-PK) was
increased in Lepob/ob Akt2lox/lox mice and normalized in livers
from Lepob/obAFP;Akt2lox/lox mice. Peroxisome proliferator-acti-
vated receptor-g (PPARg) and Cidec/Fsp27, gene products
required for development of hepatic steatosis in Lepob/ob mice,
were induced in Lepob/ob Akt2lox/lox livers, and this was prevented408 Cell Metabolism 10, 405–418, November 4, 2009 ª2009 Elsevieby loss of hepatic Akt2 (Figure 3) (Matsusue et al., 2008). Lepob/ob
Akt2lox/lox mice exhibited a slight increase in the expression of
PGC-1a, which was further enhanced in Lepob/ob AFP;Akt2lox/lox
mice (Figure 3). However, expression of medium-chain acetyl-
CoA dehydrogenase (MCAD), a transcriptional target of PGC-
1a and rate-determining enzyme in fatty acid oxidation, was
not altered in Lepob/ob AFP;Akt2lox/lox compared with Lepob/ob
Akt2lox/lox livers (Schreiber et al., 2003). In addition, the expres-
sion of carnitine palmitoyltransferase I (CPT1), another PGC-1a
target, was actually decreased in Lepob/ob AFP;Akt2lox/lox livers,
whereas the expression of the mitochondrial gene cytochrome
c oxidase subunit 7a (Cox7a) was not different between Lepob/ob
Akt2lox/lox and Lepob/ob AFP;Akt2lox/lox mice (Song et al., 2004).
Germline Akt2 Deletion Decreases Hepatic Lipid
Accumulation Resulting from Surwit High-Fat Diet
Though the Lepob/ob mouse is a robust model of obesity and
NAFLD, these mice also lack leptin, which itself plays a role in
metabolism. To complement our studies in Lepob/ob mice, we
fed Akt2/mice a Surwit diet, which induces obesity and insulin
resistance in mice through dietary enrichment of fat (58% kcal
from fat) and simple carbohydrates (25.5% kcal from carbohy-
drates, approximately half from sucrose) (Surwit et al., 1988,
1995). Male mice were given a Surwit high-fat diet (HFD) at 5
weeks of age and were maintained on the diet for 1 or 4 months;
chow-fed age-matched male mice served as controls. After
4 months on Surwit diet, Akt2+/+ mice gained more weight than
their chow-fed counterparts, an effect that was attenuated by
whole-body loss of Akt2 (Figure 4A). Though liver weight was
not significantly different between any of the groups (Figure 4B),
the increase in fed hepatic triglycerides observed in Akt2+/+mice
after 4 months on the diet was abrogated with loss of Akt2 (Fig-
ures 4C and 4D). Germline deletion of Akt2 did not change serum
triglyceride levels on Surwit HFD but did decrease fasted serum-
free fatty acids and serum ketone bodies (Table S3). Of interest,
whereas Akt2/ mice developed severe hyperglycemia on a
Lepob/ob background, Akt2/ mice on a Surwit HFD for 4
months were able to maintain fasting euglycemia by increasing
insulin levels (Figures 1E, 4E, and 4F).
AFP;Akt2lox/lox Mice Display Decreased Hepatic
Triglycerides on Surwit HFD without Significant
Changes in De Novo Lipogenesis
or Lipogenic Gene Expression
As in the previous experiments, wewanted to determine whether
the requirement for Akt2 in hepatic triglyceride accumulation
resulting from Surwit HFD was cell autonomous. Starting at
5 weeks of age, we fed male AFP;Akt2lox/lox mice Surwit HFD
for 1 or 4 months and used chow-fed age-matched male mice
as controls. During this period, there were no differences in the
weight gained on Surwit HFD between Akt2lox/lox mice and AFP;
Akt2lox/lox mice or in liver weight between any of the groups
(Figures 5A, 5B, and S3A). AFP;Akt2lox/lox mice did not differ
from Akt2lox/lox mice with regards to fasting glucose or insulin
levels, food intake, body composition, or energy expenditure
(Figures 5C, 5D, and S3B–S3D). After 1 month on Surwit HFD,
Akt2lox/lox mice had significantly increased fed hepatic triglyc-
eride levels compared to their chow-fed counterparts, an effect
that was partially ameliorated by loss of hepatic Akt2 (Figure 5E).r Inc.
Cell Metabolism
Akt2 and Hepatic SteatosisFigure 2. Lepob/ob AFP;Akt2lox/lox Mice Have Decreased Hepatic Triglyceride Levels that Correlate with a Decrease in De Novo Lipogenesis
(A and B) Body weight (A) or liver weight (B) of 12-week-old fed male mice. n = 6–8.
(C and D) Blood glucose (C) and insulin (D) levels in 8-week-old overnight fasted male mice. n = 6–9.
(E and F) Hepatic triglyceride levels of 12-week-old fed (E) or overnight fasted (F) male mice. n = 6–9.
(G) Hepatic long-chain fatty acid CoA (LLCoA) concentrations from 12-week-old overnight fasted male mice. n = 3–4.
(H) De novo lipogenesis measured as in Figure 1. n = 5–6.
All values are expressed as mean ± SEM. *p < 0.05 versus Lep+/+ Akt2lox/lox, and **p < 0.05 versus Lepob/ob Akt2lox/lox by one-way ANOVA using Newman-Keuls
posttest.Cell Metabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 409
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Akt2 and Hepatic SteatosisFigure 3. Hepatic Gene Expression in Lepob/ob AFP;Akt2lox/lox Mice
Hepatic gene expression as measured by real-time PCR of 12-week-old fed male mice. Data are presented as mRNA expression relative to that of TATA-binding
protein (TBP) and normalized to expression in Akt2lox/lox, which is set to 1.0 using the ddCT method. All values are expressed as mean ± SEM. n = 6. *p < 0.05
versus Lep+/+ Akt2lox/lox, and **p < 0.05 versus Lepob/ob Akt2lox/lox by one-way ANOVA using Newman-Keuls posttest.The same held true after 4 months on Surwit HFD, as the 4-fold
increase in fed hepatic triglycerides in Akt2lox/lox mice was
reduced by 25% with loss of hepatic Akt2. Total long-chain
fatty acyl-CoA and linoleoyl-CoA (C18:2) were decreased in
livers from mice on Surwit HFD, as the latter is an essential fatty
acid and its abundance is relatively low in coconut oil, the major
source of fat in the Surwit diet. However, there were no differ-410 Cell Metabolism 10, 405–418, November 4, 2009 ª2009 Elsevieences between mice having or lacking hepatic Akt2 (Figure 5F).
Fed serum triglycerides were increased inmice after 4months on
the diet with or without Akt2 in the liver (Table S4).
Whereas there was a significant increase in de novo lipogen-
esis in livers from mice on a Surwit HFD, this was not prevented
by deletion of Akt2 (Figure 5G). Lipogenic gene expression
paralleled this finding, as there was no decrease in hepaticr Inc.
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HFD for 1month; in fact, there was a slight increase in SREBP1c,
FAS, ACC, and L-PK expression (Figure 6). However, only SCD1
showed a significant increase in livers from Akt2lox/lox mice on
Surwit HFD compared to chow-fed animals. In addition, there
were not changes in the expression of PGC-1a, CPT1, MCAD,
or Cox7a in the AFP:Akt2lox/lox livers, and fasted or fed serum
ketone levels were similar in AFP;Akt2lox/lox mice on Surwit
HFD, suggesting that b-oxidation was not altered in these
animals (Figures 6 and S4).
AFP;Akt2lox/lox Mice Display Decreased Hepatic
Triglycerides upon Being Fed a Lard HFD
Given the differences in phenotype between mice deficient for
leptin and those fed a Surwit HFD, we tested the generality of
the requirement for Akt2 in hepatic steatosis by feedingmaleAFP;
Akt2lox/lox mice another commonly used HFD, one enriched in
fat from lard (60% kcal from fat) with a mixture of both starch
and sucrose (20% kcal from carbohydrates). After 1 month on
the lard HFD, there was an increase in hepatic triglycerides in
Akt2lox/lox mice, which was ameliorated by loss of hepatic Akt2
Figure 4. Akt2/ Mice Have Decreased
Hepatic Triglyceride Levels after 4 Months
on Surwit HFD
(A–F) Male mice were started on Surwit HFD at
5 weeks of age and sacrificed after either 1 or
4 months along with age-matched chow controls.
Shown are body weight (A) and liver weight (B);
hepatic triglyceride levels of fed (C) or overnight
fasted (D) mice; and blood glucose (E) and insulin
(F) levels from overnight fastedmice after 4 months
on HFD. Values are expressed as mean ± SEM.
n = 5–9. *p < 0.05 by one-way ANOVA using
Newman-Keuls posttest.
(Figure 7A). However, unlike the results
with the Surwit HFD, there was a signifi-
cant increase in SREBP1c expression in
the livers of Akt2lox/lox mice after 1 month
on a lard HFD, an increase that was
significantly reduced in the AFP;
Akt2lox/lox mice (Figure 7B). Other lipo-
genic genes were not increased on the
lard HFD, though there was a trend for
reduced expression in the absence of
Akt2. Nonetheless, these data again
show clearly that hepatic Akt2 is required
for hepatic lipid accumulation ensuing
from HFD feeding.
Loss of Hepatic Akt2 Decreases
Insulin Signaling in Lean Mice
but Does Not Change Downstream
Protein Phosphorylation
in Insulin-Resistant Livers
In order to gain insight into the pathways
that could be mediating Akt2’s effect on
hepatic lipid metabolism, we performed
western blots on liver extracts from Akt2lox/lox and AFP;Akt2lox/lox
mice following intraperitoneal (IP) injection of saline or insulin
(Figure 7C). Phosphorylation of Akt at residues S473 and T308
was increased in Akt2lox/lox livers injected with insulin, and this
increase was blunted in the absence of Akt2. The same pattern
held true for the phosphorylation of proline-rich Akt substrate
(PRAS) of 40 kDa, glycogen synthase kinase 3-b (GSK3b), and
tuberous sclerosis complex-2 (TSC2), whereas phosphoryla-
tion of FoxO1 did not appear to be decreased in the absence
of hepatic Akt2. Of interest, phosphorylation of these Akt
targets was increased under basal fasted conditions in AFP;
Akt2lox/loxmice, suggesting relief of a negative feedback loop in
the absence of Akt2 (Figure 7C). We also determined whether
loss of Akt2 had significant effects on hepatic insulin signaling
in Lepob/ob and HFD-fed mice, as Akt2 mediates different lipid
metabolic pathways in these two models (Figure S4). In order
to assess insulin signaling in both experimental groups in the
presence of comparable levels of insulin and glucose, Lepob/ob
Akt2lox/lox and Lepob/ob AFP;Akt2loxlox mice were submitted to a
hyperinsulinemic euglycemic clamp and liver extracts were pre-
pared; glucose and insulin levels did not differ betweenAkt2lox/loxCell Metabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 411
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from these animals after 1 month on the diet under fed condi-
tions. Insulin signaling was significantly impaired in both models
of insulin resistance, such that phosphorylation of Akt and its
targets was significantly below stimulated conditions inAkt2lox/lox
animals; moreover, loss of hepatic Akt2 in either model did not
reduce protein phosphorylation further (Figure S4).
DISCUSSION
Though insulin is well known to stimulate de novo lipogenesis in
liver, the precisemechanism bywhich this is accomplished is not
well understood. SREBP1c is clearly an important intermediate
in the transcriptional control of lipogenesis, but the pathway by
which insulin activates both processing and expression of
SREBP1c remains uncertain (Raghow et al., 2008). To some
extent, the difficulty in investigating this problem relates to the
low rates of de novo lipogenesis in the normal postabsorptive
liver, which have been estimated to contribute as little as 5%
of total triglyceride fatty acids in humans (Diraison et al., 2003).
For this reason, it has proven instructive to manipulate the meta-
bolic state of experimental organisms in order to increase fat
accumulation in the liver. In the present study, we have done
so by employing both genetic and dietary strategies and have
found a strong dependency on the presence of hepatic Akt2
for the development of steatosis and an absolute requirement
for the increase in lipogenesis. Though these data are derived
from mouse models of human disease, there is much to support
the notion that the obligatory role for Akt2 in lipid synthesis is not
unique to the insulin-resistant steatotic condition. We often see
a trend toward lower hepatic triglycerides, fatty acid synthesis,
and lipogenic gene expression in livers from normal mice on
a chow diet, and in several cohorts, these changes have reached
statistical significance (Figures 6 and 7). Thus, we can conclude
that Akt2 is required definitively for full accretion of hepatic
triglyceride during pathological states, and it is likely that this is
an extension of a requirement for the kinase in normal anabolic
lipid metabolism.
One surprising result of these studies is that, even though the
necessity of Akt2 for steatosis applies to multiple models, in at
least one, i.e., obesity induced by high-fat and sucrose feeding,
hepatic triglyceride content is reduced, but lipogenesis and
lipogenic gene expression are unchanged (Figure 5). This
contrasts with development of NAFLD in the Lepob/ob mouse,
in which the protection from steatosis is mediated, at least in
part, through preventing the stimulation of de novo lipogenesis
(Figure 2). Thus, Akt2 likely mediates insulin’s induction of
triglyceride accumulation by stimulating fatty acid synthesis as
well as processes other than de novo lipogenesis (Figure 5).Cell MOne obvious candidatemechanism is that loss of Akt2 abrogates
the normal suppression of b-oxidation produced by insulin. For
example, insulin suppresses the PGC-1a-dependent stimulation
of fatty acid oxidation, both by reducing hepatocyte cyclic AMP
and by promoting the Akt-dependent inhibition of PGC-1a
activity (Li et al., 2007). However, by several criteria, an increase
in b-oxidation is unlikely to explain the protection from steatosis
in our studies. First, though PGC-1amRNA increased in Lepob/ob
AFP;Akt2lox/lox livers, expression of the critical targetsMCAD and
CPT1 were not elevated in parallel (Figure 3) (Schreiber et al.,
2003; Song et al., 2004). Second, there were no differences in
expression of hepatic oxidative genes comparing Akt2lox/lox to
AFP;Akt2lox/lox mice placed on a Surwit HFD (Figure 6). Lastly,
RER and serum ketone bodies were largely indistinguishable in
wild-type versus AFP;Akt2lox/loxmice on either an Lepob/ob back-
ground or Surwit HFD (Figures S2 and S3 and Tables S2 and S4).
Another possible mechanism through which Akt2 could be
decreasing hepatic lipid accumulation is increased VLDL export,
as serum triglycerides were elevated in Lepob/ob Akt2/ mice
(Table S1). However, neither Lepob/ob AFP;Akt2lox/lox nor AFP;
Akt2lox/loxmice on Surwit HFD exhibited increased serum triglyc-
eride levels under fasted or fed conditions, and direct measure-
ment of triglyceride export failed to reveal a requirement for Akt2
(Tables S2 and S4 and data not shown). Thus, the necessity for
Akt2 in the development of hepatic steatosis relates to its role in
mediating induction of SREBP1c and de novo lipogenesis, as
well as other presently unidentified anabolic processes.
The role of Akt as the primary mediator of insulin’s action to
increase SREBP1c and promote lipogenesis has been a point
of some controversy. Hepatic overexpression of constitutively
active Akt increases hepatic neutral lipid dramatically by a
pathway only partially dependent on SREBP1c (Ono et al.,
2003). Similarly, forced activation of endogenous Akt by liver-
specific deletion of the lipid phosphatase Pten produces
substantial accumulation of hepatic triglyceride and increased
lipogenic gene expression, though this model is complicated
by the concomitant activation of other PI3K-dependent kinases
(Stiles et al., 2004). On the other hand, a dominant inhibitory
Akt does not block insulin’s induction of SREBP1c in tissue
culture cells, and Lepob/ob mice have markedly increased
SREBP1cmRNA in spite of significantly reduced levels of phos-
pho-Akt (Matsumoto et al., 2002; Shimomura et al., 2000). Atyp-
ical PKC (PKCl/z) proteins have received considerable attention
as obligate mediators of the effects of insulin and PI3K on
anabolic lipid metabolism and have specifically been advanced
as an alternative to Akt (Matsumoto et al., 2003; Taniguchi
et al., 2006). Matsumoto et al. showed that mice with liver-
specific deletion of PKCl have decreased SREBP1c expression
and triglyceride content, though reduced serum insulin levelsFigure 5. AFP;Akt2lox/lox Mice on Surwit HFD Have Decreased Hepatic Triglyceride Levels but Do Not Exhibit Changes in De Novo
Lipogenesis
(A–E) Male mice were started on Surwit HFD at5 weeks of age and sacrificed after either 1 or 4months alongwith age-matched chow controls. Shown are body
weight (A) and liver weight (B); blood glucose (C) and insulin (D) levels from overnight fastedmice after 4months on HFD; and hepatic triglyceride levels of fedmice
(E). n = 5–9. *p < 0.05 versus Akt2lox/lox chow, and **p < 0.05 versus Akt2lox/lox HFD by one-way ANOVA using Newman-Keuls posttest.
(F) Hepatic long-chain fatty acyl CoA (LLCoA) concentrations from overnight fastedmalemice after 1month on Surwit HFD. n = 4. *p < 0.05 versusAkt2lox/lox chow
by two-way ANOVA using Bonferroni posttest.
(G) De novo lipogenesis. Lipogenesis was assayed in male mice after 4 months on Surwit HFD as in Figure 1. n = 5. *p < 0.05 versus Akt2lox/lox chow by one-way
ANOVA using Newman-Keuls posttest. All values are expressed as mean ± SEM.etabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 413
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Akt2 and Hepatic SteatosisFigure 6. Hepatic Gene Expression in AFP;Akt2lox/lox Mice on Surwit HFD
Hepatic gene expression as measured by real-time PCR of male mice after 1 month on Surwit HFD or age-matched chow-fed controls sacrificed under fed
conditions. Data are presented as mRNA expression relative to that of TBP and normalized to expression in Akt2lox/lox chow-fed, which is set to 1.0 using the
ddCT method. All values are expressed as mean ± SEM. n = 6. *p < 0.05 versus Akt2
lox/lox chow, and **p < 0.05 versus Akt2lox/lox HFD by one-way ANOVA using
Newman-Keuls posttest.complicated the interpretation of the in vivo findings in the study
(Matsumoto et al., 2003). Kahn and colleagues undertook
a different approach, eliminating both aPKC and Akt activity by
ablation of all PI3K in the liver and then selectively introducing
constitutively activate versions of the two kinases by adeno-
virus-mediated delivery (Taniguchi et al., 2006). They found
that aPKC, but not Akt, restoredSREBP1cmRNA, but the effects
on hepatic lipids were not reported. The current studies do not
address a potential role for aPKC and thus are compatible with414 Cell Metabolism 10, 405–418, November 4, 2009 ª2009 Elseviera requirement for this kinase. However, in contrast to Taniguchi
et al., they strongly support a critical role for Akt2. Importantly,
Lepob/ob mice heterozygous for Akt2 displayed a reduction in
liver triglyceride content and de novo lipogenesis intermediate
between that of mice wild-type and null for Akt2 (Figures 1C,
1D, and 1G). This indicates that Akt2 is not only permissive for
anabolic lipid metabolism but is actually rate determining. More-
over, Lepob/ob Akt2+/mice did not display the increase in serum
glucose compared to Lepob/obmice evident in the Akt2 null mice,Inc.
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Akt2 and Hepatic Steatosisso the protection in hepatic steatosis cannot be attributed to
a worsening of the diabetes. Thus, these data support an obli-
gate role for Akt2 in the development of the steatosis of obesity
and insulin resistance, most likely reflecting the function of Akt2
in normal insulin signaling to lipid metabolism.
As shown in Figure 1E, deletion of both Akt2 and leptin
resulted in fasting hyperglycemia considerably more severe
than that in mice lacking either of the two proteins alone. This
is associated with glycosuria, which likely contributes to caloric
loss and reduction in body size in these mice (Figure 1A). In
a recent paper, Chen and colleagues attribute the severe dia-
betes observed in compound Akt1+/ Akt2/ mice to leptin
deficiency secondary to lipodystrophy (Chen et al., 2009). Our
findings cannot be explained by this model, as Akt2 deficiency
enhances the diabetes and presumably insulin resistance in
spite of the complete absence of leptin in either mouse line.
Rather, these data suggest that Akt and leptin control glucose
metabolism in parallel pathways.
A recent study examining lipid abnormalities in humans with
genetic syndromes of insulin resistance reported increased liver
fat content, lipogenesis, and serum triglycerides in several indi-
viduals with a dominant-negative mutation in Akt2 (Semple
et al., 2009). However, as pointed out by Semple et al., the one
patient studied in most detail might have had other confounding
metabolic abnormalities. Of note, like patients with an Akt2
mutation, Lepob/obmice null for Akt2 had elevated serum triglyc-
eride levels, whereas Lepob/obmice with liver-specific deletion of
Akt2 exhibit normal or reduced circulating triglyceride (Tables S1
and S2). This emphasizes the role of nonhepatic tissues in deter-
mining lipid levels and the difficulties in interpreting metabolic
data. Nonetheless, additional translational experiments will be
required to establish whether the requirement for Akt in NAFLD
is unique to rodents or does indeed recapitulate the pathophys-
iology in humans.
A longstanding paradox has been that people with T2DM and
the metabolic syndrome or rodents with equivalent metabolic
disorders have systemic insulin resistance in the face of
increased hepatic lipogenesis, a classical insulin response (Pe-
tersen et al., 2007). Though a number of models could explain
this, the concept of selective or partial insulin resistance has
received increasing recent attention (Brown and Goldstein,
2008). Both humans with insulin resistance due to inherited
mutations in the insulin receptor and mice with liver-specific
deletion of the insulin receptor exhibit hyperglycemia and hyper-
insulinemia but are protected against steatosis and hypertrigly-
ceridemia (Biddinger et al., 2008; Semple et al., 2009). This
finding is consistent with the idea that, in classical ‘‘insulin-resis-
tant’’ states, not all signaling is blunted, but, rather, some is
preserved, in particular that to lipid synthesis. Although it is likely
that the pathways regulating glucose and lipid metabolism
diverge somewhere downstream of the IRS proteins but
upstream of FoxO1 and SREBP1c, respectively, the precise
biochemical site is unknown (Dong et al., 2008; Kubota et al.,
2008;Matsumoto et al., 2007). In a recent consideration of selec-
tive insulin resistance, Brown andGoldstein wrote that the ‘‘Iden-
tification of the branch point is a central question for future
research’’ (Brown and Goldstein, 2008). In the studies presented
in this paper, we have demonstrated that the point of selective
insulin resistance lies downstream of Akt. A major unresolvedCell Mquestion is the nature of those pathways responsible for diver-
gent signaling to glucose output and lipogenesis.
EXPERIMENTAL PROCEDURES
Metabolic Measurements and Analytical Procedures
Overnight fasted mice were used for measurements of blood glucose using
a glucometer (OneTouch Ultra, Lifescan). Insulin assays were conducted on
blood collected from mice after an overnight fast by tail bleed into heparinized
tubes using an ELISA kit (Ultra Sensitive Rat Insulin ELISA kit, Crystal Chem,
Inc.). Hepatic triglycerides were measured from animals sacrificed by CO2
inhalation, snap frozen in liquid nitrogen, and stored at80C until processed.
Frozen livers were weighted and homogenized in lysis buffer (140 mM NaCl,
50 mM Tris, and 0.1% Triton-X) using a Tissuelyser (QIAGEN). Liver homoge-
nates were then incubated at 37C with 1% deoxycholate, and triglycerides
were measured calorimetrically using Infinity Triglyceride Reagent (Ther-
moDMA, Inc). Serum triglycerides, cholesterol, free fatty acids (NEFA), and
ketone bodies were analyzed from blood collected after sacrifice by cardiac
puncture using colorimetric assay kits (Infinity TG and CH reagents, Ther-
moDMA, Inc; NEFA-HR kit, Wako; and b-hydroxybutyrate LiquiColor kit,
Stanbio Laboratories, respectively). Hepatic long-chain fatty acyl-CoAs were
isolated as previously described and measured by using an API 4000 tandem
mass spectrometer (Applied Biosystems) in conjunction with two PerkinElmer
200 Seriesmicro pumps and a 200 Series autosampler (PerkinElmer) (Neschen
et al., 2005).
De Novo Lipogenesis Assay
Malemicewere fasted for 5 hr (8 AM to 1 PM), injected with D2O (400ml per 20 g
body weight), and sacrificed 3 hr later. Blood was collected by pipette after
cutting the aorta/IVC using the diaphragm as a barrier to the peritoneal cavity.
Liver was removed and snap frozen in liquid nitrogen. Palmitate was analyzed
as its trimethylsilyl derivative using gas chromatography-electron impact ioni-
zation mass spectrometry. The oven temperature was initially held for 1 min at
150C and then increased by 20C per min to 310C and maintained for 8 min.
The split ratio was 20:1 with helium flow 1 ml per min. The inlet temperature
was set at 270C, and MS transfer line was set at 310C. Under these condi-
tions, palmitate elutes at 5.7 min. The 2H-enrichment was determined
by using selective ion monitoring under electron impact ionization of m/z
313 and 314 (M+0 and M+1), 10 ms dwell time per ion. The concentration of
palmitate was determined by comparing the corrected abundance of m/z
313 to 314 to that of heptadecanoate (17:0, m/z 327). To account for possible
differences in the ionization efficiency of each fatty acid, the profile was
compared against standards prepared by mixing known quantities of each
fatty acid. Rate of lipid synthesis was determined as the percent contribution
of newly made palmitate, using the equation: % newly made palmitate = [total
2H-labeling palmitate / (2H-labeling body water 3 n)] 3 100, wherein n is the
number of exchangeable hydrogens, assumed to equal 22. The absolute
amount of newly made palmitate was determined by multiplying the % newly
made palmitate by the concentration of palmitate (Brunengraber et al., 2003;
Diraison et al., 1997; Lee et al., 1994a, 1994b).
RNA Isolation and Gene Expression Studies
Total RNA was prepared from liver using Trizol reagent (Invitrogen), followed
by chloroform extraction and DNase treatment (DNA-free kit, Ambion).
cDNA was synthesized with random decamers using the RetroScript Kit
(Ambion) and mixed with Brilliant SYBR Green QPCR Master Mix (Stratagene)
and primers as noted in Table S5. Reactions were performed on an Mx3000P
Quantitative PCR System (Stratagene). The relative amounts of specific
transcripts were calculated using TATA-binding protein (TBP) mRNA as an
invariant control by the comparative CT (ddCT) method, with the control geno-
type set to 1.0 (either Lep+/+ Akt2lox/lox or Akt2lox/lox chow fed).
Statistics
Data are presented as mean ± SEM. Data were analyzed using one-way
ANOVA using Newman-Keuls posttest, two-way ANOVA using Bonferroni
posttest, or Student’s t test assuming unequal variance with two-tailedetabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc. 415
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Akt2 and Hepatic SteatosisFigure 7. AFP;Akt2lox/lox Mice on Lard HFD Have Decreased Hepatic Triglyceride Levels and SREBP1c Expression
Male mice were started on lard HFD at 6 weeks of age and sacrificed after 1 month on diet under fed conditions along with age-matched chow-fed controls.
(A) Hepatic triglycerides.416 Cell Metabolism 10, 405–418, November 4, 2009 ª2009 Elsevier Inc.
Cell Metabolism
Akt2 and Hepatic Steatosisanalysis as described in the figure legends. Values of p < 0.05 were defined as
statistically significant.
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